{"id":"NCT03415178","sponsor":"Sanofi","briefTitle":"Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","officialTitle":"A Multicenter, Randomized, Open-label, Parallel-group Usability Study of the Commercial 1 mL Alirocumab Auto-injector Device (AI) and the New 2 mL Auto-injector Device (SYDNEY) in High or Very High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-29","primaryCompletion":"2018-08-09","completion":"2018-08-09","firstPosted":"2018-01-30","resultsPosted":"2019-09-09","lastUpdate":"2019-09-09"},"enrollment":69,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolaemia"],"interventions":[{"type":"DRUG","name":"Alirocumab SAR236553","otherNames":[]},{"type":"DEVICE","name":"Current auto-injector device (AI)","otherNames":[]},{"type":"DEVICE","name":"New auto-injector device (SYDNEY)","otherNames":[]},{"type":"DRUG","name":"Atorvastatin","otherNames":[]},{"type":"DRUG","name":"Rosuvastatin","otherNames":[]}],"arms":[{"label":"Auto-Injector Device (AI)","type":"EXPERIMENTAL"},{"label":"New Auto-injector Device (SYDNEY)","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo collect real-use (usability) data assessing the robustness and user interaction of the new alirocumab auto-injector device (which is referred to as SYDNEY), in unsupervised settings.\n\nSecondary Objective:\n\nDevice-related:\n\n* To collect real-use (usability) data assessing the robustness and user interaction of SYDNEY and the current alirocumab auto-injector device (which is referred to as AI) in supervised settings.\n\nPharmacokinetics:\n\n* To compare alirocumab pharmacokinetics (PK) administered using SYDNEY and AI.\n* To evaluate alirocumab PK administered using SYDNEY.\n\nAnti-drug antibodies:\n\n* To evaluate the development of anti-drug (alirocumab) antibodies (ADA).\n\nEfficacy/pharmacodynamics:\n\n* To compare the percent and absolute change in low-density lipoprotein cholesterol (LDL-C) using SYDNEY and AI.\n* To evaluate the percent and absolute change in LDL-C using SYDNEY.\n\nSafety:\n\n* To evaluate the safety and tolerability of alirocumab using both SYDNEY and AI.","primaryOutcome":{"measure":"Percentage of SYDNEY-Associated Product Technical Complaints (PTCs) (Overall) at the Unsupervised Injections: Single-Arm Period","timeFrame":"From Week 4 up to Week 12","effectByArm":[{"arm":"New Auto-Injector Device (SYDNEY)","deltaMin":0.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":["31879033"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":34},"commonTop":["Arthralgia","Urinary Tract Infection","Contusion","Upper Respiratory Tract Infection"]}}